I am a board-certified medical oncologist who is dedicated to treating people with melanoma and developing new treatments for this disease. I work with colleagues across MSK — physicians, nurses, and supporting staff — who all specialize in the treatment of melanoma. As a team, we spend time with our patients and their loved ones to answer their questions and recommend a treatment plan that is best for them.
My research interests focus on uveal and mucosal melanoma. These less common types of melanoma start at the back of the eye or on hairless surfaces of the body and are genetically distinct from more common skin melanomas. By better understanding these differences, I believe we can improve how we care for people with these diseases. As a junior scientist, my research has been recognized and supported with grants from the Conquer Cancer Foundation and the Ocular Melanoma Foundation in conjunction with the American Association for Cancer Research.
- Clinical Expertise: Melanoma; Uveal melanoma; Mucosal melanoma; Clinical trials of targeted or immune-based therapies
- Languages Spoken: English; Greek
- Education: MD, Rush Medical College
- Residencies: University of Chicago Medical Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Alexander N. Shoushtari
- A Phase I Study of AEB071 and BYL719 in Patients with Metastatic Uveal Melanoma
- A Phase Ib/II Study of IMCgp100 with Durvalumab and/or Tremelimumab in Cutaneous Melanoma
- A Phase II Study of Crizotinib in Patients with High-Risk Uveal Melanoma
- A Phase II Study of Trametinib with and without GSK2141795 in Patients with Advanced Uveal Melanoma
- A Phase II Study of Vorinostat for Metastatic Uveal Melanoma
- A Pilot Study of ONCOS-102 Followed by Pembrolizumab Immunotherapy in Patients with Melanoma that Has Grown after Pembrolizumab or Nivolumab
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more